The omicron single-dose booster shot for children under the age of five was approved by Pfizer and its partner BioNTech SE by the US Food and Drug Administration (FDA). According to the agency, children who have already received three doses of the initial vaccine will be eligible for the booster. After receiving the clinical trial […]
Continue Reading
According to preliminary data released by the US Centers for Disease Control and Prevention (CDC), the flu vaccine has been 68% effective at preventing hospitalizations in children, but it has been less effective at protecting seniors this season. In one study, the vaccine was effective at preventing hospitalization for seniors by 35%, and in a […]
Continue Reading
The US Food and Drug Administration (FDA) and the US Centers for Disease Control and Prevention (CDC) warned that the updated COVID-19 shot made by Pfizer and BioNtech may be linked to a stroke type in adults, and according to reports, the US CDC continues to advise people to keep up with their COVID-19 vaccinations. […]
Continue Reading
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Pfizer and BioNTech COVID-19 vaccine for use in children and infants aged 6 months to 4 years. The UK MHRA has authorized the vaccine in the new age group after the agency found to meet the standards of safety, effectiveness, and quality, with […]
Continue Reading
Cipla Limited and its wholly owned subsidiary, Cipla USA Inc., launched Leuprolide Acetate Injection Depot 22.5 mg. The injection was approved by the US Food and Drug Administration based on a New Drug Application (NDA) submitted under the regulatory pathway 505(b)(2). According to Cipla, Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for […]
Continue ReadingModerna Inc. claimed that its Omicron-focused COVID-19 vaccines had improved immune responses against BA.4 and BA.5 sub-variants of Omicron, found Moderna’s latest study. Data suggests that in adults who had been vaccinated and received booster shots, both of Moderna’s Omicron-focused vaccines, including mRNA-1273.214 and mRNA-1273.222, has produced high antibody response against BA.4 and BA.5 sub-variants […]
Continue Reading
After losing the approval for emergency use of COVID-19 vaccines, AstraZeneca has finally stopped efforts to sell its COVID-19 vaccine shots in the United States. AstraZeneca has now decided to withdraw its application for the COVID-19 vaccine Vaxzevria with the US FDA, said CEO Pascal Soriot during a press briefing. Because the US FDA has […]
Continue Reading
Using cutting-edge genome sequencing techniques, researchers at the Indian Institute of Technology (IIT), Jodhpur, have discovered variants in the COVID-19 virus’s RNA, according to officials. The fixation of these intra-host variations and mutations that results in variants have both been researched by experts. The journal “Nucleic Acid Research” has published the findings of the two-phase […]
Continue Reading
Due to low demand, about 50 million doses of Covaxin, a COVID-19 vaccine produced by Bharat Biotech, are expected to run out early in the following year. Despite having planned for production to achieve a yearly capacity of 1 billion doses by the end of 2021, Bharat Biotech, halted manufacturing the two-dose immunization Covaxin earlier […]
Continue Reading
The US Food and Drug Administration (FDA) has approved Novavax Inc.’s COVID-19 vaccine as a booster dose for adults to tackle the rapid spread of the COVID-19 virus in the country. The approval from the US FDA is set to reverse Novavax’s shares reverse course, and increase by more than 3 percent. This approval is […]
Continue Reading